NEW YORK ( TheStreet) -- Shares of Cleantech Solutions International (Nasdaq: CLNT) have taken a tremendous swing upward. The stock is trading at $6.85 as of 11:45 a.m. ET, 20.8% above Wednesday's closing price of $5.67. Volume is at 4.2 million, 41.9 times the daily average of 100,800. Cleantech Solutions International has a market cap of $5.9 million and is part of the industrial goods sector and industrial industry. Shares are up 77.2% year to date as of the close of trading on Wednesday. Cleantech Solutions International, Inc. manufactures and sells metal components and assemblies primarily used in clean technology industries in China and internationally. The company has a P/E ratio of one, equal to the average industrial industry P/E ratio and below the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Cleantech Solutions International as a hold. The company's strengths can be seen in multiple areas, such as its attractive valuation levels, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and a generally disappointing performance in the stock itself. You can view the full Cleantech Solutions International Ratings Report. See our top % gaining stocks list for other stocks that are soaring today, or get investment ideas from our investment research center. Interested in other stocks that are soaring? Get free SMS text alerts sent to you when the action happens by texting SOAR to 95370 or select from multiple alert options.
More from Markets
Trump Administration Mulling Tax Cuts to Boost the Economy
The president's team is looking at cutting payroll taxes and indexing capital-gains taxes.
How ESG Investing Can Benefit Your Portfolio and 401k
Curious about getting involved in ESG investing? Here's how it can benefit your portfolio.
Dick's Sporting Goods Reportedly Again Mulls Halt to Firearms Sales
Dick's has been the most publicly prominent among the retailers about the subject of firearms sales, CNN reports.
Moderna Stock Surges as FDA Fast Tracks Zika Vaccine
The biotech's investigational Zika vaccine is being evaluated in a Phase I study.